# A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Study · id `cardio:ct-nct01986855` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01986855](<https://clinicaltrials.gov/study/NCT01986855>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01986855

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 468 participants.

## Technical summary

Registry record NCT01986855. Randomized; double masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2016-09-28 (actual). Results posted on 2017-10-04.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 468 participants (enrolled count; ClinicalTrials.gov record NCT01986855, source copy `cardio:ctgov-nct01986855-2018-09-10`, retrieved 2026-10-26)
- Started: 2013-12-02 (actual) (ClinicalTrials.gov record NCT01986855, source copy `cardio:ctgov-nct01986855-2018-09-10`, retrieved 2026-10-26)
- Primary completion: 2016-09-28 (actual) (ClinicalTrials.gov record NCT01986855, source copy `cardio:ctgov-nct01986855-2018-09-10`, retrieved 2026-10-26)
- Completion: 2016-09-28 (actual) (ClinicalTrials.gov record NCT01986855, source copy `cardio:ctgov-nct01986855-2018-09-10`, retrieved 2026-10-26)
- Results first posted: 2017-10-04 (ClinicalTrials.gov record NCT01986855, source copy `cardio:ctgov-nct01986855-2018-09-10`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01986855-2018-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Ertugliflozin 5 mg
- Intervention (Drug): Placebo 5 mg
- Intervention (Drug): Ertugliflozin 10 mg
- Intervention (Drug): Placebo 10 mg
- Lead sponsor: Merck Sharp & Dohme LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)
- Registry lists this organization as a collaborator: Pfizer (`cardio:org-pfizer`)

## Provenance

Content hash: c656bb396bfbc759af1d999759f9e1abf112cfd53e33ca25439a8ab594f63b51
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
